The Russian Direct Investment Fund (RDIF) announced Thursday that Moscow has approved the use of the single-dose version of its COVID-19 vaccine, Sputnik Light. This is a measure that could facilitate the supply of vaccines to keep going in countries with high infection rates. Developed by the Gamaleya Institute in Moscow, the vaccine is 79.4% effective against COVID-19 compared to 91.6% of the two-dose version, according to RDIF, and costs less than $ 10 per dose.
The vaccine is for export and is designed to increase the number of people who are immune to the virus. The two-dose vaccine Sputnik V “remains the main source of vaccination in Russia,” it said in the background. The RDIF said late-stage Phase III trials with 7,000 people were ongoing in Russia, the United Arab Emirates and Ghana, among others. Interim results were expected later this month.
No serious side effects
The Phase I and Phase II results of the single-dose Sputnik Light vaccine showed that the vaccine was safe for all subjects with no serious adverse events, said RDIF. “The single-dose regime solves the challenge of immunizing large groups in a shorter time, which is particularly important in the acute phase of the spread of the coronavirus by achieving group immunity more quickly,” said Kirill Dmitriev, CEO. in a press release from RDIF.